Category Researcher Spotlight

Ran Xu, PhD

Researcher Spotlight: Ran Xu, PhD DANA FARBER CANCER INSTITUTE Many patients with mantle cell lymphoma (MCL) achieve complete remission with novel chimeric antigen receptor (CAR) T cell therapies, but some cancer cells remain that may eventually lead to relapse. Using…

David Russler-Germain, MD, PHD

Researcher Spotlight: David Russler-Germain, MD, PhD Washington University School of Medicine Although genetic mutations can drive the development of cancer, many healthy white blood cells intentionally alter their DNA to generate diverse antibody responses to infections. Dysregulation of this activity…

Patrick Reville, MD

Researcher Spotlight: Patrick Reville, MD THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Relapsed or refractory large B-cell lymphoma (LBCL) are aggressive forms of lymphoma associated with poor long-term outcomes. Chimeric antigen receptor (CAR) T cell therapies targeting CD19, engineered…

Ivan Cohen, MD

Researcher Spotlight: Ivan Cohen, PHD PERELMAN SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy that modifies a patient’s own immune cells to recognize and kill tumor cells. Anti-CD19 CAR T…